MedTrace Logo

HIV Vaccine Trial in Thai Adults

NCT00223080 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 16402

Last updated 2019-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in healthy Thai volunteers.

Conditions

  • HIV Infection

Interventions

BIOLOGICAL

ALVAC-HIV vCP1521 + AIDSVAX

Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL

OTHER

ALVAC Placebo + AIDSVAX Placebo

ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection

Sponsors & Collaborators

  • United States Army Medical Materiel Development Activity

    collaborator FED

  • Armed Forces Research Institute of Medical Sciences, Thailand

    collaborator OTHER_GOV

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • MCM Vaccines B.V.

    collaborator INDUSTRY

  • VaxGen

    collaborator INDUSTRY

  • The Emmes Company, LLC

    collaborator INDUSTRY

  • Ministry of Health, Thailand

    collaborator OTHER_GOV

  • Mahidol University

    collaborator OTHER

  • Royal Thai Army Medical Department

    collaborator OTHER_GOV

  • Tripler Army Medical Center

    collaborator FED

  • Henry M. Jackson Foundation for the Advancement of Military Medicine

    collaborator OTHER

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Supachai Rerks-Ngarm, MD · Ministry of Health, Thailand

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2006-07-31
Completion
2009-06-30

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00223080 on ClinicalTrials.gov